Medtronic's Omniasecure™ defibrillation lead has successfully received approval from the U.S. Food and Drug Administration (FDA) for use in conduction system pacing therapy.

老虎证券2026/03/23 13:33

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

International Energy Agency: Emergency reserve oil releases will continue to increase until the end of February

路透社•2026/11/13 14:18

Cardano roadmap consists of five phases, Plomin hard fork completes the final governance phase

Odaily星球日报•2026/11/13 13:56

BUZZ-Newsmax shares rise due to unexpected third-quarter profitability

路透社•2026/11/13 13:46

NZD/USD Price Forecast: Bears gain momentum to test 19-month lows at 0.5527

FXStreet•2026/11/13 13:24